Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia

Leukemia & Lymphoma
E TusetD Catovsky

Abstract

T-cell prolymphocytic leukaemia (T-PLL) is an aggressive disease often resistant to conventional chemotherapy. Long lasting remissions with the monoclonal antibody CAMPATH-1H (anti-CD52) have been documented. We describe two unusual T-PLL patients treated successfully first with CAMPATH-1H in whom, at the time of relapse, the cells underwent a phenotypic switch with loss of CD52 expression. In one of them, cytogenetic analysis demonstrated the same chromosome abnormalities in the cells at diagnosis and relapse. The reasons for the immunophenotypic changes are unknown but it is likely that loss of CD52 antigen expression contributed to the resistance to CAMPATH-1H in one of the patients when re-treated.

Citations

Jul 23, 2004·Seminars in Hematology·Jeanette Lundin, Anders Osterborg
Nov 29, 2014·The Journal of Investigative Dermatology·Constantijn J M HalkesMaarten H Vermeer
Jan 9, 2004·Pediatric Clinics of North America·Jonathan P PearlAllan D Kirk
Apr 18, 2006·Seminars in Oncology·Biju KrishnanClaire Dearden
Sep 2, 2014·Clinical Lymphoma, Myeloma & Leukemia·Andrew C Cannon, Fausto R Loberiza
Oct 15, 2018·Current Hematologic Malignancy Reports·Paola GhioneMarco Ruella

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.